Shire eyes Europe with UCB drug buy

In nabbing rights to UCB's attention deficit Equasym drugs, Shire has built a bridge into Europe, a market the company hasn't yet mined for ADHD riches. Release l Report 

Suggested Articles

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.

With two more former Insys executives facing prison time, another is claiming sexist hiring as an excuse for her role in a kickback scheme.